Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population

被引：0
|
作者：
Kappos, L. [1 ,2 ,3 ,4 ]
Bar-Or, A. [5 ]
Cree, B. [6 ]
Fox, R. [7 ]
Giovannoni, G. [8 ]
Gold, R. [9 ]
Vermersch, P. [10 ]
Bhasin, P. [11 ]
Arnould, S. [12 ]
Sidorenko, T. [12 ]
Wallstroem, E. [12 ]
机构：
[1] Univ Basel Hosp, Neurol, Dept Med, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Neurol, Dept Clin Res, CH-4031 Basel, Switzerland
[3] Univ Basel Hosp, Neurol, Dept Biomed, CH-4031 Basel, Switzerland
[4] Univ Basel Hosp, Neurol, Dept Biomed Engn, CH-4031 Basel, Switzerland
[5] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada
[6] Univ Calif San Francisco, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA
[7] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA
[8] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England
[9] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
[10] Univ Lille, Dept Neurol, Lille, France
[11] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[12] Novartis Pharma AG, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P649
引用
收藏
页码：317 / 318
页数：2
相关论文
共 50 条
  • [31] Effect of Siponimod on Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study
    Vennersch, P.
    Fox, R. J.
    Arnold, D. L.
    Giovannoni, G.
    Cree, B. A. C.
    Bar-Or, A.
    Golds, R.
    Benedict, R. H. B.
    Piaui-Meier, D.
    Arnould, S.
    Ritter, S.
    Dahlke, F.
    Karlsson, G.
    Kappos, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 478 - 478
  • [32] Effect of siponimod on cortical grey matter and thalamic volume in patients with secondary progressive multiple sclerosis - results of the EXPAND study
    Arnold, D. L.
    Fox, R.
    Bar-Or, A.
    Cree, B. A. C.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Meier, D. Piani
    Arnould, S.
    Ritter, S.
    Dahlke, F.
    Tomic, D.
    Kappos, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 151 - 152
  • [33] Siponimod improves cognitive processing speed in patients with secondary progressive multiple sclerosis: EXPAND subgroup analyses
    Benedict, R.
    Fox, R.
    Tomic, D.
    Cree, B.
    Vermersch, P.
    Giovannoni, G.
    Bar-or, A.
    Gold, R.
    Ritter, S.
    Karlsson, G.
    Wolf, C.
    Kappos, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 868 - 868
  • [34] Current diagnostics of secondary progressive form of multiple sclerosis and its treatment with siponimod
    Stourac, P.
    [J]. CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (04) : 364 - 367
  • [35] Long-term Efficacy of Siponimod Treatment for up to 5 Years in Patients with Secondary Progressive Multiple Sclerosis: Analysis of the EXPAND Extension Study
    Kappos, L.
    Giovannoni, G.
    Gold, R.
    Fox, R. J.
    Vermersch, P.
    Benedict, R. H. B.
    Bar-or, A.
    Rouyrres, N.
    Piani-Meier, D.
    Ritter, S.
    Kilaru, A.
    Dahlke, F.
    Karlsson, G.
    Cree, B. A. C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 337 - 337
  • [36] Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report
    Rot, Uros
    Jerala, Miha
    Ledinek, Alenka Horvat
    Jakob, Gregor Brecl
    [J]. JOURNAL OF NEUROLOGY, 2024, 271 (08) : 4794 - 4812
  • [37] Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study
    Arnold, Douglas L.
    Cree, Bruce A. C.
    Bar-Or, Amit
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Meier, Daniela Piani
    Arnould, Sophie
    Ritter, Shannon
    Karlsson, Goeril
    Kappos, Ludwig
    Fox, Robert
    [J]. NEUROLOGY, 2020, 94 (15)
  • [38] Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Arnould, Sophie
    Sidorenko, Tatiana
    Wolf, Christian
    Wallstrom, Erik
    Dahlke, Frank
    [J]. NEUROLOGY, 2017, 88
  • [39] Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study
    Cohan, S.
    Hua, L. H.
    Bar-Or, A.
    Lublin, F. D.
    Meng, X.
    Cox, G. M.
    Coyle, P. K.
    Fox, R. J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 590 - 591
  • [40] Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
    Gold, Ralf
    Piani-Meier, Daniela
    Kappos, Ludwig
    Bar-Or, Amit
    Vermersch, Patrick
    Giovannoni, Gavin
    Fox, Robert J.
    Arnold, Douglas L.
    Benedict, Ralph H. B.
    Penner, Iris-Katharina
    Rouyrre, Nicolas
    Kilaru, Ajay
    Karlsson, Goril
    Ritter, Shannon
    Dahlke, Frank
    Hach, Thomas
    Cree, Bruce A. C.
    [J]. JOURNAL OF NEUROLOGY, 2022, 269 (09) : 5093 - 5104
12345